Status: open
Acella (NP Thyroid false advertising)
Defendant: Acella Pharmaceuticals
Pharmaceutical maker Acella agreed to pay $41.4 million to settle allegations of false advertising related to the company’s NP Thyroid product. The lawsuit alleged that Acella falsely claimed that the thyroid drug contained a specific amount of the active ingredient; some batches of the medication allegedly contained more and others contained less. If you filled a prescription for NP Thyroid between May 12, 2018, and April 30, 2021, you may be eligible for a payment.